Cosmos Health Inc.

COSM

US2214133058

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.65 ^USD	+25.75%		+34.35%	-53.90%

Mar. 21	Cosmos Health Inc. Commences Development of Cloudscreen 2.0 the New Iteration of Its Next Generation AI Drug Repurposing Platform	CI
Mar. 18	Cosmos Health Inc. Receives Regulatory Approval to Sell Sky Premium Life Products in UAE Nutritional Supplements Market	CI

Cosmos Health Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023

November 20, 2023 at 04:06 pm EST

Cosmos Health Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 12.82 million compared to USD 12.02 million a year ago. Net loss was USD 3.35 million compared to USD 1.97 million a year ago. Basic loss per share from continuing operations was USD 0.27 compared to USD 1.93 a year ago. Diluted loss per share from continuing operations was USD 0.27 compared to USD 1.93 a year ago.
For the nine months, sales was USD 37.54 million compared to USD 38.3 million a year ago. Net loss was USD 4.79 million compared to USD 3.01 million a year ago. Basic loss per share from continuing operations was USD 0.42 compared to USD 29.35 a year ago. Diluted loss per share from continuing operations was USD 0.42 compared to USD 29.35 a year ago.

Latest news about Cosmos Health Inc.

Cosmos Health Inc. Commences Development of Cloudscreen 2.0 the New Iteration of Its Next Generation AI Drug Repurposing Platform	Mar. 21	CI
Cosmos Health Inc. Receives Regulatory Approval to Sell Sky Premium Life Products in UAE Nutritional Supplements Market	Mar. 18	CI
Cosmos Health Acquires Rights to Patent for Drug Targeting Central Nervous System Cancers	Dec. 07	MT
Cosmos Health Files Patent Application for Obesity, Weight Management Product With European Patent Office	Dec. 01	MT
Tranche Update on Cosmos Health Inc.'s Equity Buyback Plan announced on January 24, 2023.	Nov. 20	CI
Cosmos Health Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 20	CI
Cosmos Health Insider Bought Shares Worth $158,806, According to a Recent SEC Filing	23-10-12	MT
Sector Update: Health Care Stocks Softer Late Afternoon	23-10-11	MT
Sector Update: Health Care Stocks Drop Wednesday Afternoon	23-10-11	MT
Cosmos Health Says it has Agreed to Buy Cloudscreen in a Cash-and-Stock Deal.	23-10-11	MT
Cosmos Health Inc. has entered into a purchase agreement to acquire Cloudscreen.	23-10-10	CI
Cosmos Health to Continue to Pursue Active Ongoing Acquisitions	23-10-05	CI
Sector Update: Health Care Stocks Slipping Late Afternoon	23-09-27	MT
Sector Update: Health Care Stocks Retreating Wednesday Afternoon	23-09-27	MT
Sector Update: Health Care	23-09-27	MT
Cosmos Health Says Exploring Spinoff of R&D Division Into Publicly Listed Company; Shares Drop	23-09-27	MT
Cosmos Health Inc. agreed to Spin-Off Research and development (R&D) division of Cosmos Health Inc.	23-09-26	CI
Cosmos Health Inc. Announces Executive and Board Changes	23-09-22	CI
Cosmos Health Forms Strategic Partnership with C.A.PAPAELLINAS Group	23-09-20	MT
Cosmos Health Inc. Announces Strategic Collaboration with C.A.PAPAELLINAS Group	23-09-20	CI
Cosmos Health Inc. Provides Earnings Guidance for the Year 2023	23-09-14	CI
Sector Update: Health Care Stocks Declining Late Afternoon	23-09-12	MT
Sector Update: Health Care Stocks Advancing Tuesday Afternoon	23-09-12	MT
Sector Update: Health Care	23-09-12	MT
Cosmos Health Issues 2026 Outlook; Shares Jump	23-09-12	MT

Chart Cosmos Health Inc.

Duration

Period

More charts

Company Profile

Cosmos Health Inc. is a global healthcare company. The Company owns a portfolio of pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe and C-Sept. Through its subsidiary, Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It distributes a line of pharmaceuticals and Para pharmaceuticals, including branded generics and over the counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It is also engaged in the research and development (R&D) of patented nutraceuticals and specialized root extracts as well as in the R&D of complex generics and OTC products. It offers Cloudscreen, a multimodal platform specialized in drug repurposing, a process of uncovering new target proteins. It is also specialized in the storage and distribution of pharmaceutical and Para pharmaceutical goods.

Sector

Pharmaceuticals

Calendar

2024-05-14 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.65 USD

Average target price

4 USD

Spread / Average Target

+515.38%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
COSMOS HEALTH INC.	-53.90%	10.95M
MCKESSON CORPORATION	+17.35%	71.39B
CARDINAL HEALTH, INC.	+2.39%	25.1B
SINOPHARM GROUP CO. LTD.	+5.38%	8.59B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+6.69%	8.19B
HUADONG MEDICINE CO., LTD	-20.96%	7.91B
H. LUNDBECK A/S	+0.49%	4.54B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+17.12%	4.31B
EBOS GROUP LIMITED	-3.38%	3.93B
GALENICA AG	-2.61%	3.86B

Pharmaceuticals Wholesale